Innovent Biologics Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
565 / 1361
Position in country
5408 / 7387
Return on Assets, %
-5.4
-40.3
Net income margin, %
-25.4
-180
EBITDA margin, %
-24
-168.2
Debt to Equity, %
28.9
3.2
Intangible assets and goodwill, %
6.1
0.2
Revenue CAGR 3Y, %
17.3
12.5
Revenue Y, % chg
29.2
0
P/BV
4.4
1.8
P/S
9
10.3
EV/S
7.8
7.5
EV/EBITDA
-52
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
-63.9
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Imeik Technology Development Co Ltd
00%
-
Chongqing Zhifei Biological Products Co Ltd
00%
-
Shanghai RAAS Blood Products Co Ltd
00%
-
Hualan Biological Engineering Inc
00%
-
Beijing Tiantan Biological Products Corp Ltd
00%
-
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
00%
-
Akeso Inc
00%
-
Gan & Lee Pharmaceuticals
00%
-
Innovent Biologics Inc
00%
-
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
China
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
7732.5
Ticker
IVBIY.PK
ISIN
US45783L1017
IPO date
2018-10-31
Availability on Russian exchanges
No
Reporting for
2024-03-20
Date fact. publication of reports
2023-12-31
Company Description
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: